2537-P: Body Composition and Functional Outcomes of HM17321, a CRFR2-Selective UCN2 Analog, Alone and in Combination with Myostatin/Activin Inhibition in DIO Mice
Diabetes · 05.06.2026 · 75 (Supplement_1)
DOI: 10.2337/db26-2537-p ↗Kurz gefasst
Fachartikel in der Zeitschrift Diabetes, erschienen am 05.06.2026. Verfasst von SEON MYEONG LEE und 8 weiteren Autor:innen.
Abstract (Originalsprache)
Introduction and Objective: The current paradigm in obesity management is shifting from maximizing weight loss to improving weight loss quality (WLQ). Clinical studies combining incretin therapies with myostatin/activin pathway inhibition, such as bimagrumab (Bima), suggest benefits for WLQ. HM17321 is a CRFR2-selective UCN2 analog developed to promote fat-selective body weight loss (BWL) with favorable metabolic effects. This study evaluated HM17321 alone or with Bima in male and female DIO mice.
Methods
Male and female DIO mice were treated for 4 weeks with HM17321 alone or with Bima. Body weight and body composition were assessed, and skeletal muscle function was evaluated using wire hang and grip strength tests.
Results
HM17321 (100 nmol/kg) induced significant BWL in both male and female DIO mice (-17.5%, -12.7% vs. day 0), whereas Bima (20 mg/kg) alone showed minimal or opposite effects (-1.1%, +3.1%). The combination treatment (COMBO) achieved greater BWL (-22.6%, -24.8%). HM17321 reduced fat mass with modest lean mass gains in both sexes (-41.1%/+3.2% and -34.0%/+3.5% vs. baseline), whereas Bima primarily increased lean mass with marginal fat mass reduction (-15.7%/+12.9% and -15.6%/+18.6%). COMBO showed the most pronounced improvement in body composition, with substantial fat mass reduction and lean mass gain (-67.9%/+19.2% and -69.3%/+25.0%) compared with either monotherapy. Improvements in muscle function were confirmed following HM17321 treatment; however, no functional benefit was observed in the Bima monotherapy or COMBO groups despite pronounced muscle mass accrual in both sexes.
Conclusion
HM17321 induced fat-selective BWL with functional lean mass gain in both sexes, supporting its potential as a novel foundational WLQ therapy. These findings provide proof-of-concept for additional benefits of incorporating myostatin/activin pathway inhibition for body weight and body composition, warranting longer-term evaluation. Disclosure S. Lee: None. E. Kim: None. H. Kwon: Employee; Current; Hanmi Pharm. Co., Ltd. D. Lee: None. J. Kim: Employee; Current; Hanmi Pharm. Co., Ltd. J. Kim: None. S. Bae: None. S. Lee: Employee; Current; Hanmi Pharm. Co., Ltd. I. Choi: None.
Zitieren
APA
LEE, S. M., KIM, E., KWON, H., LEE, D., KIM, J. A., KIM, J. K., BAE, S., LEE, S. H., & CHOI, I. Y. (2026). 2537-P: Body Composition and Functional Outcomes of HM17321, a CRFR2-Selective UCN2 Analog, Alone and in Combination with Myostatin/Activin Inhibition in DIO Mice. Diabetes, 75(Supplement_1). https://doi.org/10.2337/db26-2537-p
Vancouver
LEE SM, KIM E, KWON H, LEE D, KIM JA, KIM JK, et al. 2537-P: Body Composition and Functional Outcomes of HM17321, a CRFR2-Selective UCN2 Analog, Alone and in Combination with Myostatin/Activin Inhibition in DIO Mice. Diabetes. 2026;75(Supplement_1). doi:10.2337/db26-2537-p
BibTeX
@article{LEE2026,
author = {LEE, SEON MYEONG and KIM, EUNSEON and KWON, HYUNJOO and LEE, DAHAE and KIM, JEONG A and KIM, JUNG KUK and BAE, SUNGMIN and LEE, SANG HYUN and CHOI, IN YOUNG},
title = {2537-P: Body Composition and Functional Outcomes of HM17321, a CRFR2-Selective UCN2 Analog, Alone and in Combination with Myostatin/Activin Inhibition in DIO Mice},
journal = {Diabetes},
year = {2026},
volume = {75},
number = {Supplement_1},
doi = {10.2337/db26-2537-p}
}
EUVIMED